Literature DB >> 393389

Cis-dichlorodiammineplatinum(II) in metastatic soft tissue sarcomas.

C P Karakousis, O A Holtermann, E D Holyoke.   

Abstract

cis-Dichlorodiammineplatinum(II) was given to 13 patients with metastatic sarcomas following failure in two previous chemotherapy protocols. Two of these patients had complete regression which lasted 6 months in one patient and is still present after 8 months in the other. One patient had a greater than 50% regression which lasted 5 months. Three patients had disease stabilization for 2 months each. cis-Dichlorodiammineplatinum(II), as a single agent, was well-tolerated with no significant renal or auditory toxicity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 393389

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  [Chemotherapy of soft tissue sarcomas].

Authors:  D K Hossfeld; S Seeber; E Siemers; C G Schmidt
Journal:  Langenbecks Arch Chir       Date:  1981

2.  A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma.

Authors:  M L Keohan; M R Grever; S P Balcerzak; K Antman
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 3.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

4.  High-dose adriamycin (ADM) and cis-platinum (DDP) in advanced soft-tissue sarcomas and invasive thymomas. A pilot study.

Authors:  T H Klippstein; P S Mitrou; K J Kochendörfer; L Bergmann
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  High-dose VP16 cisplatinum in soft tissue sarcoma of children.

Authors:  M Grabois; D Frappaz; E Bouffet; C Carrie; D Bouhour; T Philip; M Brunat-Mentigny
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.

Authors:  Ji Young Moon; Seung-Woo Baek; Hyewon Ryu; Yoon-Seok Choi; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.

Authors:  W Budach; V Budach; M Stuschke; B Schmauder; P Reipke; M E Scheulen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.